Trial Profile
A French Open-label Extension Study of Canakinumab in Patients Who Participated in International Phase III Studies CACZ885G2301E1 or CACZ885G2306 in Systemic Juvenile Idiopathic Arthritis and CACZ885N2301 in Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 May 2020
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Hereditary autoinflammatory diseases; Juvenile rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Novartis
- 08 Jan 2019 Status changed from active, no longer recruiting to completed.
- 04 Dec 2018 Planned End Date changed from 22 Dec 2018 to 24 Dec 2018.
- 04 Dec 2018 Planned primary completion date changed from 22 Dec 2018 to 24 Dec 2018.